Today we are excited to announce that we have entered into an agreement with Innate Pharma which sees its portfolio of patents related to its ADC transglutaminase conjugation technology assigned to Araris: ararisbiotech.com/docs/240924_ar… #ADC #AntibodyDrugConjugates #Patents #Agreement

Our CEO, Dragan Grabulovski, was recently interviewed by Brad Loncar from Biotech TV at our labs near Zurich. Check out the full video: biotechtv.com/post/araris-bi… #ADC #AntibodyDrugConjugates #ADCTechnology #Patents #Agreement

We are pleased to see our innovative approach to multi-payload ADCs featured in @BioProcess Online! Learn more about our efforts to enhance the performance of ADCs and mitigate side effects: Araris Doubles Down With Dual-payload ADC (bioprocessonline.com)

Next Tuesday, the Araris team will be participating at the Festival of Biologics in Basel. If you are attending and would like to connect with Dragan, Philipp or Romain please email: [email protected] #Araris #ADC #Conference

Next week our CSO Philipp Spycher will be delivering his keynote presentation, Novel Dual-Payload ADCs That Show Excellent Biophysical Properties and High Efficacy in Vivo, at PEGS Europe on 6 Nov in Barcelona at 14:20 CET. pegsummiteurope.com/engineering-co…

We are very excited to announce a major research collaboration and option to license agreement with Chugai Pharmaceutical! ararisbiotech.com/docs/250106_25… #Araris #ADCs

On this #WorldCancerDay, we honor all those whose lives have been touched by cancer. We envision a world without chemotherapy and are committed to developing a new generation of #ADCs to tackle the persistent challenges of cancer resistance. #Araris #CancerResearch

In Citeline's latest “Scrip Asks...What Does 2025 Hold For Biopharma?” our CEO, Dragan Grabulovski, shares his insights on the exciting potential of ADCs. Read more here: insights.citeline.com/scrip/scrip-as… #Biopharma #Araris #DrugDevelopment #ADC

We are pleased to see that our publication in ChemBioChem describing a new technology for developing ADCs that supports our foundational technology platform is currently one of the most read publications in the journal. Read the publication: …mistry-europe.onlinelibrary.wiley.com/doi/10.1002/cb…

Excited to be part of World ADC’s 15th Annual #WorldADC Conference in London on March 3-6. Join us and other industry leaders to learn more about the latest advancements in #ADCTechnology. #Araris #WorldADC #Conference

Excited to join the BioProcess Online Virtual Panel on March 25 to explore the future of ADCs. Register now to learn more about our multi-payload ADC approach: event.on24.com/wcc/r/4858517/… #Araris #ADCs #BioProcessOnline

We are excited to announce the publication of our latest preclinical data in AACR’s Molecular Cancer Therapeutics, showcasing the power of our next-generation ADC technology: ararisbiotech.com/docs/250403_25… #ADCTherapeutics #OncologyInnovation #Biotech #ArarisBiotech

We are pleased to see our innovative antibody conjugation technology featured on the cover of the April issue of ChemBioChem! Read the publication here: …mistry-europe.onlinelibrary.wiley.com/doi/10.1002/cb… #ADC #ChemBioChem #Araris

Next week, our co-founder and CTO, Isabella Attinger-Toller, will be presenting our latest next-generation ADC technology developments at the AACR Annual Meeting 2025 in Chicago! #AACR25 #ADCTherapeutics #CancerResearch #ArarisBiotech #Conference

We are thrilled to announce a research agreement with Johnson & Johnson to develop next-generation antibody drug conjugates (ADCs) using our AraLinQ™ technology. Read the full announcement here: ararisbiotech.com/docs/araris_jn… #Araris #CancerResearch #ADCs #Partnership

Our CBO, Filippo Mulinacci, sat down with Emma Ulker from Nature Biotechnology, to speak about his career so far. Read the full article here: nature.com/articles/d4158… #Araris #Interview #Career #Biotech #ADC

Our CBO, Filippo Mulinacci, will be attending BIO International in Boston from 16-19 June. Reach out to find out more about our innovative ADC pipeline and multi-payload AraLinQ™ technology. #Araris #BIO2025 #ADCs #conference #networking

Araris Biotech is heading to #BIO2025 in Boston (June 16-19)! Meet our team to learn about our ADC pipeline and multi-payload AraLinQ™ technology. DM to connect! #Biotech #ADC #Araris #CancerResearch #ADCs

Our CSO, Philipp Spycher, will speak at the Antibody Industrial Symposium (AIS) on June 25! Tune in for insights on the future of ADCs and biotech innovation. #AIS2025 #ADC #Biotech

Proud to announce our founding team has won the 2025 Strüngmann Award for breakthrough ADC technology! Thank you for recognizing our mission!💙 globenewswire.com/news-release/2…